📚 Volume 30, Issue 4
📋 ID: 60HYay2
Authors
Bader S Alotaibi, Roomi Yousuf***, Reyaz Ahmad, Bilal Ahmad , Altaf Bandy,
xxx
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is connected to high rates of morbidity and challenging-to-treat infections. S. aureus bacteremia, which has high rates of morbidity, mortality and can lead to severe infections
such as infective endocarditis or sepsis, as well as metastatic infections. The majority of S. aureus bacteremia cases
worldwide are caused by MRSA, which has worse clinical outcomes than methicillin-sensitive S. aureus. Infections
caused by the nosocomial pathogen Methicillin Resistant S. aureus (MRSA) at the hospital as well as in the
community are considered a serious global threat. Despite having a wide range of genetic variations, the
epidemiology of MRSA is principally characterized by the recurrent appearance of epidemic strains. MRSA
continues to be a serious clinical hazard despite recent decreases in occurrence in some areas, and its morbidity and
death rates are consistently high. The evaluation of both novel antibiotics and ancillary parts of care, such as
infectious disease consultation, echocardiography, and source control, is necessary for successful therapy, which is
still difficult to achieve. Leukocyte lysis and tissue necrosis are caused by the virulence factor Panton-Valentine
leukocidin (PVL), which is secreted by some strains. Skin and soft tissue infections (SSTIs) are the most common
illnesses caused by PVL-associated S. aureus (PVL-SA), although it can also cause invasive infections such as
necrotizing pneumonia. Community-associated methicillin-susceptible S. aureus (CA-MSSA) and methicillinresistant S. aureus both carry it (CA-MRSA). MRSA strains are endemic in many parts of Saudi Arabia and it
accounts for 23-54% of all clinical isolates. Significantly, 54.2% of Panton-Valentine leukocidin (PVL) genes were
found in MRSA strains inside the kingdom. Vancomycin is a drug of choice to treat MRSA infections. The patients
admitted to Prince, Mutib, hospital from March 2019 to May 2020 were screened for the prevalence of MRSA.
Compact Vitek -2 (biomeriux Leon, France) was used for the identification and antimicrobial sensitivity (AST) test.
A total of 64/978 (6.5%) MRSA and 25/978 (2.5%) CoNS were isolated from urine, blood, sputum, nasal swab,
throat swab, tracheal swabs, and pleural fluid. Cephamycins were found 100% resistant to vancomycin-resistant
MRSA were found in our study..
such as infective endocarditis or sepsis, as well as metastatic infections. The majority of S. aureus bacteremia cases
worldwide are caused by MRSA, which has worse clinical outcomes than methicillin-sensitive S. aureus. Infections
caused by the nosocomial pathogen Methicillin Resistant S. aureus (MRSA) at the hospital as well as in the
community are considered a serious global threat. Despite having a wide range of genetic variations, the
epidemiology of MRSA is principally characterized by the recurrent appearance of epidemic strains. MRSA
continues to be a serious clinical hazard despite recent decreases in occurrence in some areas, and its morbidity and
death rates are consistently high. The evaluation of both novel antibiotics and ancillary parts of care, such as
infectious disease consultation, echocardiography, and source control, is necessary for successful therapy, which is
still difficult to achieve. Leukocyte lysis and tissue necrosis are caused by the virulence factor Panton-Valentine
leukocidin (PVL), which is secreted by some strains. Skin and soft tissue infections (SSTIs) are the most common
illnesses caused by PVL-associated S. aureus (PVL-SA), although it can also cause invasive infections such as
necrotizing pneumonia. Community-associated methicillin-susceptible S. aureus (CA-MSSA) and methicillinresistant S. aureus both carry it (CA-MRSA). MRSA strains are endemic in many parts of Saudi Arabia and it
accounts for 23-54% of all clinical isolates. Significantly, 54.2% of Panton-Valentine leukocidin (PVL) genes were
found in MRSA strains inside the kingdom. Vancomycin is a drug of choice to treat MRSA infections. The patients
admitted to Prince, Mutib, hospital from March 2019 to May 2020 were screened for the prevalence of MRSA.
Compact Vitek -2 (biomeriux Leon, France) was used for the identification and antimicrobial sensitivity (AST) test.
A total of 64/978 (6.5%) MRSA and 25/978 (2.5%) CoNS were isolated from urine, blood, sputum, nasal swab,
throat swab, tracheal swabs, and pleural fluid. Cephamycins were found 100% resistant to vancomycin-resistant
MRSA were found in our study..
📝 How to Cite
Bader S Alotaibi, Roomi Yousuf***, Reyaz Ahmad, Bilal Ahmad , Altaf Bandy, (2023). "Hospital-Acquired Methicillin-resistant Staphylococcus aureus Bacteremia in Prince Muteb Hospital � One Year Retrospective Study.". Wulfenia, 30(4).